Lubeluzole Repositioning As Chemosensitizing Agent on Multidrug-Resistant Human Ovarian A2780/DX3 Cancer Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Nov 26

PMID 36431971

Authors

Maurizio Viale

Giovanni Lentini

Rosaria Gangemi

Patrizio Castagnola

Gualtiero Milani

Silvia Ravera

Nadia Bertola

Antonio Carrieri

Maria Maddalena Cavalluzzi

Affiliations

Soon will be listed here.

Abstract

In a previous paper, we demonstrated the synergistic action of the anti-ischemic lubeluzole (Lube S) on the cytotoxic activity of doxorubicin (Dox) and paclitaxel in human ovarian cancer A2780 and lung cancer A549 cells. In the present paper, we extended in vitro the study to the multi-drug-resistant A2780/DX3 cell line to verify the hypothesis that the Dox and Lube S drug association may potentiate the antitumor activity of this anticancer compound also in the context of drug resistance. We also evaluated some possible mechanisms underlying this activity. We analyzed the antiproliferative activity in different cancer cell lines. Furthermore, apoptosis, Dox accumulation, MDR1 downregulation, ROS, and NO production in A2780/DX3 cells were also evaluated. Our results confirm that Lube S improves Dox antiproliferative and apoptotic activities through different mechanisms of action, all of which may contribute to the final antitumor effect. Moderate stereoselectivity was found, with Lube S significantly more effective than its enantiomer (Lube R) and the corresponding racemate (Lube S/R). Docking simulation studies on the ABCB1 Cryo-EM structure supported the hypothesis that Lube S forms a stable MDR1-Dox-Lube S complex, which hampers the protein transmembrane domain flipping and blocks the efflux of Dox from resistant A2780/DX3 cells. In conclusion, our in vitro studies reinforce our previous hypothesis for repositioning the anti-ischemic Lube S as a potentiating agent in anticancer chemotherapy.

References

Liu R, Zhang Y, Chen Y, Qi J, Ren S, Xushi M . A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells. J Pharm Sci. 2010; 99(7):3266-75. DOI: 10.1002/jps.22082. View

Micucci M, Viale M, Chiarini A, Spinelli D, Frosini M, Tavani C . 3-Aryl-4-nitrobenzothiochromans -dioxide: From Calcium-Channel Modulators Properties to Multidrug-Resistance Reverting Activity. Molecules. 2020; 25(5). PMC: 7179187. DOI: 10.3390/molecules25051056. View

De Ryck M, Keersmaekers R, Duytschaever H, Claes C, Clincke G, Janssen M . Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther. 1996; 279(2):748-58. View

Desaphy J, Carbonara R, Costanza T, Lentini G, Cavalluzzi M, Bruno C . Molecular dissection of lubeluzole use-dependent block of voltage-gated sodium channels discloses new therapeutic potentials. Mol Pharmacol. 2012; 83(2):406-15. DOI: 10.1124/mol.112.080804. View

Alam A, Kung R, Kowal J, McLeod R, Tremp N, Broude E . Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A. 2018; 115(9):E1973-E1982. PMC: 5834697. DOI: 10.1073/pnas.1717044115. View

BERENBAUM M . What is synergy?. Pharmacol Rev. 1989; 41(2):93-141. View

Raspollini M, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A . Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol. 2004; 92(3):806-12. DOI: 10.1016/j.ygyno.2003.12.023. View

Zhang J, Ming C, Zhang W, Okechukwu P, Morak-Mlodawska B, Pluta K . 10-3,6-Diazaphenothiazine induces G/M phase cell cycle arrest and caspase-dependent apoptosis and inhibits cell invasion of A2780 ovarian carcinoma cells through the regulation of NF-κB and (BIRC6-XIAP) complexes. Drug Des Devel Ther. 2017; 11:3045-3063. PMC: 5661483. DOI: 10.2147/DDDT.S144415. View

Gandolfo C, Sandercock P, Conti M . Lubeluzole for acute ischaemic stroke. Cochrane Database Syst Rev. 2002; (1):CD001924. DOI: 10.1002/14651858.CD001924. View

10.

Choi Y, Yu A . ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2013; 20(5):793-807. PMC: 6341993. DOI: 10.2174/138161282005140214165212. View

11.

OBoyle N, Banck M, James C, Morley C, Vandermeersch T, Hutchison G . Open Babel: An open chemical toolbox. J Cheminform. 2011; 3:33. PMC: 3198950. DOI: 10.1186/1758-2946-3-33. View

12.

Oliveri V, Lanza V, Milardi D, Viale M, Maric I, Sgarlata C . Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents. Metallomics. 2017; 9(10):1439-1446. DOI: 10.1039/c7mt00156h. View

13.

Cavalluzzi M, Viale M, Bruno C, Carocci A, Catalano A, Carrieri A . A convenient synthesis of lubeluzole and its enantiomer: evaluation as chemosensitizing agents on human ovarian adenocarcinoma and lung carcinoma cells. Bioorg Med Chem Lett. 2013; 23(17):4820-3. DOI: 10.1016/j.bmcl.2013.06.077. View

14.

Mayur Y, Jagadeesh S, Thimmaiah K . Targeting calmodulin in reversing multi drug resistance in cancer cells. Mini Rev Med Chem. 2006; 6(12):1383-9. DOI: 10.2174/138955706778993021. View

15.

Alam A, Kowal J, Broude E, Roninson I, Locher K . Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science. 2019; 363(6428):753-756. PMC: 6800160. DOI: 10.1126/science.aav7102. View

16.

Juang S, Xie K, Xu L, Shi Q, Wang Y, Yoneda J . Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. Hum Gene Ther. 1998; 9(6):845-54. DOI: 10.1089/hum.1998.9.6-845. View

17.

Cianfriglia M, Willingham M, Tombesi M, Scagliotti G, Frasca G, Chersi A . P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells. Int J Cancer. 1994; 56(1):153-60. DOI: 10.1002/ijc.2910560127. View

18.

Cappelli E, Cuccarolo P, Stroppiana G, Miano M, Bottega R, Cossu V . Defects in mitochondrial energetic function compels Fanconi Anaemia cells to glycolytic metabolism. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(6):1214-1221. DOI: 10.1016/j.bbadis.2017.03.008. View

19.

Teodori E, Dei S, Scapecchi S, Gualtieri F . The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco. 2002; 57(5):385-415. DOI: 10.1016/s0014-827x(02)01229-6. View

20.

Gatti L, Zunino F . Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005; 111:127-48. DOI: 10.1385/1-59259-889-7:127. View